[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biologic Therapeutic Drugs: Technologies and Global Markets

January 2024 | 253 pages | ID: BF43D81C4EA7EN
BCC Research

US$ 5,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Scope:

The current report offers a detailed picture of the biologics market.

This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2028, as well as key market players.

This report details market shares for biologics based on product, source, application and geography. Based on product, the market is segmented into therapeutic proteins, cell and gene therapy, vaccines, and other segments. Based on application, the market is segmented into cancer, autoimmune conditions, aesthetics, eye disorders, and others. Based on source, the market is segmented into human, animal, micro-organism, fermented cell and others

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028. Estimated values are based on product manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:
  • 38 data tables and 59 additional tables
  • An overview of the global markets for biologic therapeutic drugs.
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
  • Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
  • A discussion of the market’s opportunities and challenges, as well as emerging technologies and regulations.
  • Overview of the sustainability trends, with emphasis on consumer attitudes, companies’ ESG scores, the future of ESG, case studies and the ESG practices of companies.
  • A discussion of the technological means that the leading biopharmaceutical companies are using.
  • Evaluation of the ongoing clinical trials and R&D activity for biologics production.
  • A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top selling biologics, as well as their patent expiries.
  • Review of emerging technologies and patents.
  • An overview of the competitive landscape, including a look at the major vendors’ market shares, recent M&A activity, and venture funding outlook.
  • Company profiles of major players within the industry, including Amgen Inc., Abbive Inc., Eli Lilly And Co., Novartis Ag, and Glaxosmithkline Plc
CHAPTER 1 INTRODUCTION

Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What’s New in this Update?
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Market Overview

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Biopharmaceutical Industry Structure
Origins of Biotechnology
Involvement of Large Pharmaceutical Companies
Overview of Biologics
Biologics Manufacturing
Biopharmaceutical Manufacturing Process
The Preparation Process
Expression Systems for Therapeutic Protein Production
Advantages of E. coli for Microbial Production
Mammalian Cell Therapeutic Protein Production
FDA Regulation of Biologics

CHAPTER 4 MARKET DYNAMICS

Market Drivers
Overview
Rising Prevalence of Chronic Diseases
Advancement in Biologics
Development in Cell and Gene Therapy Methodology
Increase in Infectious and Chronic Diseases
Market Restraints
Emergence of Biosimilars
Expensive Cost of Biologics
Market Opportunities
Opportunities in Emerging Nations

CHAPTER 5 MARKET BREAKDOWN BY PRODUCT SEGMENT

Global Market for Biological Therapeutic Drugs by Product
Therapeutic Proteins
Vaccines
Cell and Gene Therapy
Others

CHAPTER 6 MARKET BREAKDOWN BY APPLICATION

Global Market for Biological Therapeutic Drugs by Application
Cancer
Autoimmune Conditions
Aesthetics
Eye Disorder
Others

CHAPTER 7 MARKET BREAKDOWN BY SOURCE

Global Market for Biological Therapeutic Drugs by Source
Human
Animal
Microorganisms
Fermented Cells
Other Sources

CHAPTER 8 MARKET BREAKDOWN BY REGION

Global Market for Biological Therapeutic Drugs by Region
North America
Europe
Asia-Pacific
Rest of World
GCC Countries
Brazil
Rest of World Countries

CHAPTER 9 EMERGING TECHNOLOGY FOR BIOLOGICS MANUFACTURING

Introduction
AcceTT & BacSec Technologies
Single-use Technologies
Cell and Gene Therapy (CGT)
Doggybone DNA (dbDNA)
Animal Plasma Isolation
Hybridoma Generation
B Cell Screening
Display Technologies
Emerging Biologics Discovery and Generation Technologies
Emerging Trends in Biologic Production Technologies
Example of New Developments by Companies
Samsung Biologics
AstraZeneca
Genentech Inc. (Member of Roche family)

CHAPTER 10 SUSTAINABILITY IN THE BIOPHARMACEUTICALS AND BIOLOGICS INDUSTRY: AN ESG PERSPECTIVE

Importance of ESG in the Biopharmaceuticals Manufacturing Industry
ESG Ratings and Metrics: Understanding the Data
ESG Practices in the Biopharmaceuticals and Biologics Manufacturing Industry
BCC Research Viewpoint

CHAPTER 11 M&A AND VENTURE FUNDING OUTLOOK

M&A Analysis
M&A Deals 2018–2023
Top Biologic Drug Startups
Flourishing Biotech Startups (2023)

CHAPTER 12 FDA APPROVED MONOCLONAL ANTIBODIES, 1986-2023


CHAPTER 13 COMPETITIVE LANDSCAPE

Porter’s Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Competitive Rivalry/Degree of Competition

CHAPTER 14 COMPANY PROFILES

ABBVIE INC.
AMGEN INC.
BAXTER INTERNATIONAL INC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
CSL LTD.
DENDREON PHARMACEUTICALS LLC.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GLAXOSMITHKLINE PLC
GLYCOTOPE GMBH
GRIFOLS S.A.
JSC PHARMSTANDARD
KEDRION S.P.A.
LONZA
MERCK & CO. INC.
NOVARTIS AG
OCTAPHARMA AG
RELIANCE LIFE SCIENCES
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

Summary Table : Global Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 1 : Biologic Orphan Drugs, by Trade Name and Indication
Table 2 : Global Cancer Incidence: Both Sexes
Table 3 : Approved Cellular and Gene Therapy Products
Table 4 : Global Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 5 : Global Market for Biological Therapeutic Proteins, by Region, Through 2028
Table 6 : Global Market for Biological Therapeutic Vaccines, by Region, Through 2028
Table 7 : Global Market for Cell and Gene Therapy, by Region, Through 2028
Table 8 : Global Market for Other Biological Therapeutic Drug Products, by Region, Through 2028
Table 9 : Global Market for Biological Therapeutic Drugs, by Application, Through 2028
Table 10 : Global Market for Biological Therapeutics in Cancer Applications, by Region, Through 2028
Table 11 : Global Market for Biological Therapeutics in Autoimmune Condition Applications, by Region, Through 2028
Table 12 : Global Market for Biological Therapeutics in Aesthetic Applications, by Region, Through 2028
Table 13 : Global Market for Biological Therapeutics in Eye Disorder Applications, by Region Through 2028
Table 14 : Global Market for Biological Therapeutics in Other Applications, by Region, Through 2028
Table 15 : Global Market for Biological Therapeutic Drugs, by Source, Through 2028
Table 16 : Global Market for Human Sources of Biological Therapeutics, by Region, Through 2028
Table 17 : Global Market for Animal Sources of Biological Therapeutics, by Region, Through 2028
Table 18 : Global Market for Microorganism Sources of Biological Therapeutics, by Region, Through 2028
Table 19 : Global Market for Fermented Cell Sources of Biological Therapeutics, by Region, Through 2028
Table 20 : Global Market for Other Sources of Biological Therapeutics, by Region, Through 2028
Table 21 : Global Market for Biological Therapeutic Drugs, by Region, Through 2028
Table 22 : North American Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 23 : North American Market for Biological Therapeutic Drugs, by Application Segment, Through 2028
Table 24 : North American Market for Biological Therapeutic Drugs, by Source Segment, Through 2028
Table 25 : North American Market for Biological Therapeutic Drugs, by Country, Through 2028
Table 26 : European Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 27 : European Market for Biological Therapeutic Drugs, by Application Segment, Through 2028
Table 28 : European Market for Biological Therapeutic Drugs, by Source Segment, Through 2028
Table 29 : European Market for Biological Therapeutic Drugs, by Country, Through 2028
Table 30 : Asia-Pacific Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 31 : Asia-Pacific Market for Biological Therapeutic Drugs, by Application Segment, Through 2028
Table 32 : Asia-Pacific Market for Biological Therapeutic Drugs, by Source Segment, Through 2028
Table 33 : Asia-Pacific Market for Biological Therapeutic Drugs, by Country, Through 2028
Table 34 : Japanese Market Statistics
Table 35 : Rest of World Market for Biological Therapeutic Drugs, by Product Segment, Through 2028
Table 36 : Rest of World Market for Biological Therapeutic Drugs, by Application Segment, Through 2028
Table 37 : Rest of World Market for Biological Therapeutic Drugs, by Source Segment, Through 2028
Table 38 : Rest of World Market for Biological Therapeutic Drugs, by Country, Through 2028
Table 39 : Brazilian Approved Biologics/Biosimilars, 2023
Table 40 : Emerging Trends in Biologics
Table 41 : ESG Understanding Data
Table 42 : ESG: Environmental Performance
Table 43 : ESG: Social Performance
Table 44 : ESG: Governance Performance
Table 45 : Recently Received Awards by Major Companies
Table 46 : ESG Rankings for Major Research Antibody Companies, 2023*
Table 47 : U.S. FDA-approved Monoclonal Antibodies in the Market, 2023
Table 48 : Porter's Five Forces Analysis
Table 49 : AbbVie Inc.: Company Snapshot
Table 50 : AbbVie Inc.: Product Portfolio
Table 51 : Amgen Inc: Company Snapshot
Table 52 : Amgen Inc.: Product Portfolio
Table 53 : Baxter International Inc.: Company Snapshot
Table 54 : Baxter International Inc.: Product Portfolio
Table 55 : Baxter International Inc.: Recent Developments, 2021
Table 56 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 57 : Boehringer Ingelheim International GmbH: Annual Revenue, 2022
Table 58 : Boehringer Ingelheim International GmbH: Products
Table 59 : CSL Ltd: Company Snapshot
Table 60 : CSL Ltd.: Products Portfolio
Table 61 : CSL Ltd.: Recent Developments, 2023
Table 62 : Dendreon Pharmaceuticals LLC.: Company Snapshot
Table 63 : Dendreon Pharmaceuticals LLC: Product Portfolio
Table 64 : Eli Lilly and Co.: Company Snapshot
Table 65 : Eli Lilly and Co.: Product Portfolio
Table 66 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 67 : F. Hoffmann-La Roche Ltd.: Financials, 2021-2022
Table 68 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 69 : GlaxoSmithKline Plc: Company Snapshot
Table 70 : GlaxoSmithKline Plc: Products and Services
Table 71 : Glycotope GmbH: Company Snapshot
Table 72 : Glycotope GmbH: Product Portfolio
Table 73 : Grifols S.A.: Company Snapshot
Table 74 : Grifols S.A.: Product Portfolio
Table 75 : Grifols S.A.: Recent Developments, 2020
Table 76 : JSC Pharmstandard: Company Snapshot
Table 77 : JSC Pharmstandard: Product Portfolio
Table 78 : Kedrion S.p.A.: Company Snapshot
Table 79 : Kedrion S.p.A.: Products and Services
Table 80 : Kedrion S.p.A.: Recent Developments, 2020
Table 81 : Lonza: Company Snapshot
Table 82 : Lonza: Product Portfolio
Table 83 : Merck & Co. Inc.: Company Snapshot
Table 84 : Merck & Co. Inc.: Annual Revenue, 2022
Table 85 : Merck & Co. Inc.: Products
Table 86 : Novartis AG: Company Snapshot
Table 87 : Novartis AG: Product Portfolio
Table 88 : Octapharma AG: Company Snapshot
Table 89 : Octapharma AG: Products and Services
Table 90 : Octapharma AG: Recent Developments, 2020
Table 91 : Reliance Life Sciences: Company Snapshot
Table 92 : Reliance Life Sciences: Product Portfolio
Table 93 : Sanofi: Company Snapshot
Table 94 : Sanofi: Products and Services
Table 95 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 96 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

LIST OF FIGURES

Summary Figure : Global Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 1 : Approved Biologics, in 2022
Figure 2 : Biological Therapeutic Drugs Market Dynamics
Figure 3 : FDA-approved Cell and Gene Therapies
Figure 4 : Global Projected Diabetes, Patients Aged 20-79, 2010 and 2030
Figure 5 : Global Infectious Diseases Outbreak, between 2020 and 2022
Figure 6 : Global Infectious Diseases Outbreak, 2022
Figure 7 : Global Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 8 : Global Market for Biological Therapeutic Proteins, 2020-2028
Figure 9 : Global Market for Biological Therapeutic Proteins, by Region, 2020-2028
Figure 10 : Global Market for Biological Therapeutic Vaccines, 2020-2028
Figure 11 : Global Market for Biological Therapeutic Vaccines, by Region, 2020-2028
Figure 12 : Global Market for Cell and Gene Therapy, 2020-2028
Figure 13 : Global Market for Cell and Gene Therapy, by Region, 2020-2028
Figure 14 : Investments in Cell and Gene Therapy Companies
Figure 15 : Global Market for Other Biological Therapeutic Drug Products, 2020-2028
Figure 16 : Global Market for Other Biological Therapeutic Drug Products, by Region, 2020-2028
Figure 17 : Global Market Shares of Biological Therapeutic Drugs, by Application, 2022
Figure 18 : Global Market for Biological Therapeutics in Cancer Applications, 2020-2028
Figure 19 : Global Market for Biological Therapeutics in Cancer Applications, by Region, 2020-2028
Figure 20 : Global Market for Biological Therapeutics in Autoimmune Condition Applications, 2020-2028
Figure 21 : Global Market for Biological Therapeutics in Autoimmune Condition Applications, by Region, 2020-2028
Figure 22 : Global Market for Biological Therapeutics in Aesthetic Applications, 2020-2028
Figure 23 : Global Market for Biological Therapeutics in Aesthetic Applications, by Region, 2020-2028
Figure 24 : Global Market for Biological Therapeutics in Eye Disorder Applications, 2020-2028
Figure 25 : Global Market for Biological Therapeutics in Eye Disorder Applications, by Region, 2020-2028
Figure 26 : Global Market for Biological Therapeutics in Other Applications, 2020-2028
Figure 27 : Global Market for Biological Therapeutics in Other Applications, by Region, 2020-2028
Figure 28 : Global Market Shares of Biological Therapeutic Drugs, by Source, 2022
Figure 29 : Global Market for Human Sources of Biological Therapeutics, 2020-2028
Figure 30 : Global Market for Human Sources of Biological Therapeutics, by Region, 2020-2028
Figure 31 : Global Market for Animal Sources of Biological Therapeutics, 2020-2028
Figure 32 : Global Market for Animal Sources of Biological Therapeutics, by Region, 2020-2028
Figure 33 : Global Market for Microorganism Sources of Biological Therapeutics, 2020-2028
Figure 34 : Global Market for Microorganism Sources of Biological Therapeutics, by Region, 2020-2028
Figure 35 : Global Market for Fermented Cell Sources of Biological Therapeutics, 2020-2028
Figure 36 : Global Market for Fermented Cell Sources of Biological Therapeutics, by Region, 2020-2028
Figure 37 : Global Market for Other Sources of Biological Therapeutics, 2020-2028
Figure 38 : Global Market for Other Sources of Biological Therapeutics, by Region, 2020-2028
Figure 39 : Global Market for Biological Therapeutic Drugs, by Region, 2020-2028
Figure 40 : Global Market Shares of Biological Therapeutic Drugs, by Region, 2022
Figure 41 : North American Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 42 : North American Market Shares of Biological Therapeutic Drugs, by Application Segment, 2022
Figure 43 : North American Market Shares of Biological Therapeutic Drugs, by Source Segment, 2022
Figure 44 : North American Market Shares of Biological Therapeutic Drugs, by Country, 2022
Figure 45 : U.S. Market for Biological Therapeutic Drugs, 2020-2028
Figure 46 : Canadian Market for Biological Therapeutic Drugs, 2020-2028
Figure 47 : Mexican Market for Biological Therapeutic Drugs, 2020-2028
Figure 48 : European Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 49 : European Market Shares of Biological Therapeutic Drugs, by Application Segment, 2022
Figure 50 : European Market Shares of Biological Therapeutic Drugs, by Source Segment, 2022
Figure 51 : European Market Shares of Biological Therapeutic Drugs, by Country, 2022
Figure 52 : German Market for Biological Therapeutic Drugs, 2020-2028
Figure 53 : U.K. Market for Biological Therapeutic Drugs, 2020-2028
Figure 54 : French Market for Biological Therapeutic Drugs, 2020-2028
Figure 55 : Italian Market for Biological Therapeutic Drugs, 2020-2028
Figure 56 : Spanish Market for Biological Therapeutic Drugs, 2020-2028
Figure 57 : Dupixent Unit Sales by Specialty in Danish Healthcare Region, 2020 and 2021
Figure 58 : Rest of European Market for Biological Therapeutic Drugs, 2020-2028
Figure 59 : Asia-Pacific Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 60 : Asia-Pacific Market Shares of Biological Therapeutic Drugs, by Application Segment, 2022
Figure 61 : Asia-Pacific Market Shares of Biological Therapeutic Drugs, by Source Segment, 2022
Figure 62 : Asia-Pacific Market Shares of Biological Therapeutic Drugs, by Country, 2022
Figure 63 : Chinese Market for Biological Therapeutic Drugs, 2020-2028
Figure 64 : Japanese Market for Biological Therapeutic Drugs, 2020-2028
Figure 65 : Indian Market for Biological Therapeutic Drugs, 2020-2028
Figure 66 : Australia and New Zealand Market for Biological Therapeutic Drugs, 2020-2028
Figure 67 : Rest of Asia-Pacific Market for Biological Therapeutic Drugs, 2020-2028
Figure 68 : Rest of World Market for Biological Therapeutic Drugs, 2020-2028
Figure 69 : Rest of World Market Shares of Biological Therapeutic Drugs, by Product Segment, 2022
Figure 70 : Rest of World Market Shares of Biological Therapeutic Drugs, by Application Segment, 2022
Figure 71 : Rest of World Market Shares of Biological Therapeutic Drugs, by Source Segment, 2022
Figure 72 : Rest of World Market Shares of Biological Therapeutic Drugs, by Country, 2022
Figure 73 : GCC Countries Market for Biological Therapeutic Drugs, 2020-2028
Figure 74 : Brazilian Market for Biological Therapeutic Drugs, 2020-2028
Figure 75 : Rest of Row Countries Market for Biological Therapeutic Drugs, 2020-2028
Figure 76 : New Forms of DNA
Figure 77 : Snapshot - Key Trends in the Growth of Biologics Production Technologies
Figure 78 : Snapshot - Key ESG Trends in Biopharmaceutical and Biologics Industry
Figure 79 : Global Manufacturer Market Shares of Biological Therapeutics, 2022
Figure 80 : AbbVie Inc.: Annual Revenue, 2020-2022
Figure 81 : AbbVie Inc.: Revenue Share, by Products, 2022
Figure 82 : AbbVie Inc.: Revenue Share, by Country, 2022
Figure 83 : Amgen Inc.: Annual Revenue, 2019-2022
Figure 84 : Amgen Inc.: Revenue Share, by Products, 2022
Figure 85 : Amgen Inc.: Revenue Share, by Country, 2022
Figure 86 : Baxter International Inc.: Annual Revenue, 2019-2022
Figure 87 : Baxter International Inc.: Revenue Share, by Business Unit, 2022
Figure 88 : Baxter International Inc.: Revenue Share, by Region, 2022
Figure 89 : Boehringer Ingelheim International GmbH: Annual Revenue, 2021 and 2022
Figure 90 : Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, 2022
Figure 91 : Boehringer Ingelheim International GmbH: Revenue Shares, by Country/Region, 2022
Figure 92 : CSL Ltd.: Financials, 2020-2022
Figure 93 : CSL Ltd.: Revenue Share, by Segment, 2022
Figure 94 : CSL Ltd.: Revenue Share, by Country/Region, 2022
Figure 95 : Eli Lilly and Co.: Annual Revenue, 2020-2022
Figure 96 : Eli Lilly and Co.: Revenue Share, by Products, 2022
Figure 97 : Eli Lilly and Co.: Revenue Share, by Region, 2022
Figure 98 : F. Hoffmann-La Roche Ltd.: Financials, 2021 and 2022
Figure 99 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, 2022
Figure 100 : F. Hoffmann-La Roche Ltd.: Diagnostic Revenue Shares, by Country/Region, 2022
Figure 101 : GlaxoSmithKline Plc: Annual Revenue, 2020-2022
Figure 102 : GlaxoSmithKline Plc: Revenue Share, by Business Segment, 2022
Figure 103 : GlaxoSmithKline Plc: Revenue Share, by Region, 2022
Figure 104 : Grifols S.A.: Financials, 2020-2022
Figure 105 : Grifols S.A.: Revenues Share, by Segment, 2022
Figure 106 : Grifols S.A.: Revenue Share, by Region, 2022
Figure 107 : Kedrion S.p.A.: Financials, 2020-2022
Figure 108 : Lonza: Annual Revenue, 2020-2022
Figure 109 : Lonza: Revenue Shares, by Region, 2022
Figure 110 : Lonza: Revenue Shares, by Business Segment, 2022
Figure 111 : Merck & Co. Inc.: Revenue Shares, by Business Unit, 2022
Figure 112 : Merck & Co. Inc.: Annual Revenue, 2021 and 2022
Figure 113 : Merck & Co. Inc.: Revenue Shares, by Country/Region, 2022
Figure 114 : Novartis AG.: Annual Revenue, 2020-2022
Figure 115 : Novartis AG: Revenue Share, by Region, 2022
Figure 116 : Novartis AG: Revenue Share, by Business Segment, 2022
Figure 117 : Octapharma AG: Financials, 2020-2022
Figure 118 : Sanofi: Annual Revenue, 2020-2022
Figure 119 : Sanofi: Revenue Share, by Business Segment, 2022
Figure 120 : Sanofi: Revenue Share, by Region, 2019
Figure 121 : Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2020-2022
Figure 122 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2022
Figure 123 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2022


More Publications